Compare · NVO vs ZVRA
NVO vs ZVRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zevra Therapeutics Inc. (ZVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 301.4x ZVRA ($715.0M).
- ZVRA has been more active in the news (10 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 9 for ZVRA).
- Company
- Novo Nordisk A/S
- Zevra Therapeutics Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $715.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 10
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZVRA
- Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium
- Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Chief Legal & Compliance Thompson Rahsaan sold $474,774 worth of shares (42,666 units at $11.13) as part of a pre-agreed trading plan, decreasing direct ownership by 53% to 37,569 units (SEC Form 4)
- Director Watton Corey Michael exercised 12,300 shares at a strike of $4.97 and sold $138,377 worth of shares (12,300 units at $11.25) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Zevra Therapeutics Inc.
- SEC Form 10-Q filed by Zevra Therapeutics Inc.
- Zevra Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
- Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference
- Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)